IMR Press / FBS / Volume 2 / Issue 1 / DOI: 10.2741/S71

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Biomarkers of myocardial injury after cardiac arrest or myocardial ischemia

Show Less
1 Weil Institute of Critical Care Medicine, 35100 Bob Hope DR, Rancho Mirage, California 92270, USA
2 Department of Anesthesia and Critical Care Medicine, Catania University-Hospital, via Santa Sofia 78 - Building 29,95123 Catania, Italy
3 Department of Biological Chemistry, Medical Chemistry and Molecular Biology, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy

*Author to whom correspondence should be addressed.

Academic Editor: Xueji Zhang

Front. Biosci. (Schol Ed) 2010, 2(1), 373–391;
Published: 1 January 2010
(This article belongs to the Special Issue Biosensors and their applications)

Outcomes of victims of cardiac arrest or acute myocardial ischemic events have improved with advances in medical therapy. Heart failure, however, remains a leading cause of morbidity and mortality after these conditions have occurred. Clinical features may be useful for predicting patients who are at risk of developing such complications, but they lack of sensitivity and specificity. Biomarkers have been therefore suggested as means to provide relevant prognostic information. The more commonly used biomarkers after cardiovascular ischemic events, including cardiac arrest, are creatin kinases and troponins. In addition, natriuretic peptides and C-reactive protein have gained great interest and now sufficient data has been collected such to justify their clinical applicability. Finally, several other novel biomarkers, to be used after resuscitation from cardiac arrest or more generally after a myocardial ischemic event, have been anticipated. Nevertheless, the "perfect" biomarker, able to provide diagnosis and prognosis with high sensitivity and specificity does not exit. A multimarker strategy that categorizes patients based on the number of elevated biomarkers at presentation is therefore suggested.

Back to top